Soleno Therapeutics Reports Strong Q4 Earnings, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy SLNO?
Source: Benzinga
Soleno Therapeutics' stock fell 8.78% as it crossed below the 5-day SMA, reflecting broader market weakness with the Nasdaq-100 down 1.68% and S&P 500 down 1.01%.
Despite the stock's decline, Soleno Therapeutics reported a Q4 GAAP EPS of $0.80, exceeding expectations by $0.09, and a revenue of $91.73 million, surpassing forecasts by $3.18 million. This strong financial performance indicates sustained improvement in profitability and boosts investor confidence, even amid a challenging market environment.
The company's robust cash flow and optimistic market outlook, including plans for EU regulatory approval and capturing new patient start forms, suggest a positive trajectory for future growth. Investors may view this earnings report as a strong foundation for Soleno's ongoing market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 40.610
Low
75.00
Averages
110.50
High
125.00
Current: 40.610
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Filing Deadline: ClaimsFiler reminds Soleno Therapeutics investors that they must file lead plaintiff applications by May 5, 2026, for shares purchased between March 26 and November 4, 2025, highlighting the legal risks facing investors.
- Legal Allegations: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding undisclosed safety concerns related to DCCR, the company's only commercial product.
- Safety Concerns: The lawsuit claims that the Phase 3 clinical trial for DCCR did not adequately disclose potential safety issues, including excessive fluid retention among participants, which could adversely affect the drug's market acceptance and commercial viability.
- Commercial Viability Risks: The undisclosed safety risks raise significant concerns about DCCR's commercial viability, potentially leading to higher patient discontinuation rates, reluctance from prescribers, and possible legal and reputational fallout, exacerbating investor anxiety.
See More
Class Action Reminder for Soleno Therapeutics Shareholders
- Lawsuit Background: Robbins LLP reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that a class action has been filed, alleging the company failed to disclose safety concerns regarding the DCCR clinical trial, resulting in investor losses.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to DCCR during its Phase 3 clinical trial, including fluid retention in participants, which materially decreased the drug's commercial viability and increased risks of patient discontinuation and prescriber reluctance.
- Stock Price Volatility: Following the August 15, 2025, report by Scorpion Capital revealing clinical trial issues, Soleno's stock price dropped nearly 12% over two days; additionally, after a patient death linked to DCCR was reported on September 10, 2025, the stock fell nearly 19% in two days.
- Financial Impact: On November 4, 2025, Soleno reported its Q3 financial results, with CEO Bhatnagar noting that the Scorpion report disrupted DCCR's launch trajectory, leading to fewer patient start forms and increased discontinuations, causing the stock to plummet from nearly $64 on November 4 to about $47 on November 5, a one-day decline of approximately 27%.
See More
Soleno Therapeutics Class Action Notice Issued
- Class Action Initiation: Soleno Therapeutics faces a class action lawsuit for failing to disclose safety concerns related to its DCCR drug, with investors able to apply as lead plaintiffs by May 5, 2026, potentially impacting the company's reputation and stock price.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed significant safety risks during DCCR's clinical trials, raising investor doubts about its commercial viability and potentially leading to greater legal liabilities.
- Stock Price Volatility: Following the release of a critical report, Soleno's stock price plummeted nearly 27% within days, reflecting market concerns over the safety and commercial prospects of its product, which may affect future fundraising efforts.
- Legal Representation Strength: Robbins Geller, representing the plaintiffs, has recovered $8.4 billion for investors over the past five years, showcasing its strong track record in securities fraud cases, which may enhance the likelihood of success in this lawsuit.
See More
Faruqi & Faruqi Encourages Soleno Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Soleno Therapeutics, particularly for investors who purchased or acquired securities between March 26, 2025, and November 4, 2025, highlighting the firm's commitment to investor rights.
- Investor Contact Information: Investors who suffered losses are encouraged by Faruq & Faruq's Securities Litigation Partner Josh Wilson to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310), ensuring they receive timely legal support.
- Class Action Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the urgency and significance of the legal process.
- Potential Impact Assessment: This investigation may negatively affect Soleno's stock price and corporate reputation, prompting investors to stay informed on developments to protect their interests.
See More
Class Action Lawsuit Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26, 2025, and November 4, 2025, resulting in investor losses, highlighting significant transparency issues within the company.
- Allegation Details: The complaint claims that Soleno and its executives systematically minimized and failed to disclose substantial safety concerns related to the DCCR clinical trial, including excessive fluid retention among participants, which raises serious doubts about the drug's commercial viability and could undermine investor confidence.
- Investor Impact: The undisclosed safety risks associated with DCCR may lead to higher patient discontinuation rates, prescriber reluctance, and potential legal and reputational fallout, negatively affecting the company's market performance and investor sentiment.
- Action Recommendation: Affected investors are advised to apply for lead plaintiff status by May 5, 2026, to seek recovery in the lawsuit, emphasizing the legal rights and protective measures available to investors facing corporate misconduct.
See More
Class Action Lawsuit Announced Against Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for common stock purchasers between March 26 and November 4, 2025, indicating potential investor losses due to undisclosed risks.
- Compensation Structure: Participants in the class action may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights in securities litigation.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety evidence related to its DCCR drug clinical trials, which could lead investors to misjudge the company's future commercial viability and associated risks.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Filing Deadline: ClaimsFiler reminds Soleno Therapeutics investors that they must file lead plaintiff applications by May 5, 2026, for shares purchased between March 26 and November 4, 2025, highlighting the legal risks facing investors.
- Legal Allegations: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding undisclosed safety concerns related to DCCR, the company's only commercial product.
- Safety Concerns: The lawsuit claims that the Phase 3 clinical trial for DCCR did not adequately disclose potential safety issues, including excessive fluid retention among participants, which could adversely affect the drug's market acceptance and commercial viability.
- Commercial Viability Risks: The undisclosed safety risks raise significant concerns about DCCR's commercial viability, potentially leading to higher patient discontinuation rates, reluctance from prescribers, and possible legal and reputational fallout, exacerbating investor anxiety.
See More
Class Action Reminder for Soleno Therapeutics Shareholders
- Lawsuit Background: Robbins LLP reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that a class action has been filed, alleging the company failed to disclose safety concerns regarding the DCCR clinical trial, resulting in investor losses.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to DCCR during its Phase 3 clinical trial, including fluid retention in participants, which materially decreased the drug's commercial viability and increased risks of patient discontinuation and prescriber reluctance.
- Stock Price Volatility: Following the August 15, 2025, report by Scorpion Capital revealing clinical trial issues, Soleno's stock price dropped nearly 12% over two days; additionally, after a patient death linked to DCCR was reported on September 10, 2025, the stock fell nearly 19% in two days.
- Financial Impact: On November 4, 2025, Soleno reported its Q3 financial results, with CEO Bhatnagar noting that the Scorpion report disrupted DCCR's launch trajectory, leading to fewer patient start forms and increased discontinuations, causing the stock to plummet from nearly $64 on November 4 to about $47 on November 5, a one-day decline of approximately 27%.
See More
Soleno Therapeutics Class Action Notice Issued
- Class Action Initiation: Soleno Therapeutics faces a class action lawsuit for failing to disclose safety concerns related to its DCCR drug, with investors able to apply as lead plaintiffs by May 5, 2026, potentially impacting the company's reputation and stock price.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed significant safety risks during DCCR's clinical trials, raising investor doubts about its commercial viability and potentially leading to greater legal liabilities.
- Stock Price Volatility: Following the release of a critical report, Soleno's stock price plummeted nearly 27% within days, reflecting market concerns over the safety and commercial prospects of its product, which may affect future fundraising efforts.
- Legal Representation Strength: Robbins Geller, representing the plaintiffs, has recovered $8.4 billion for investors over the past five years, showcasing its strong track record in securities fraud cases, which may enhance the likelihood of success in this lawsuit.
See More
Faruqi & Faruqi Encourages Soleno Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Soleno Therapeutics, particularly for investors who purchased or acquired securities between March 26, 2025, and November 4, 2025, highlighting the firm's commitment to investor rights.
- Investor Contact Information: Investors who suffered losses are encouraged by Faruq & Faruq's Securities Litigation Partner Josh Wilson to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310), ensuring they receive timely legal support.
- Class Action Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the urgency and significance of the legal process.
- Potential Impact Assessment: This investigation may negatively affect Soleno's stock price and corporate reputation, prompting investors to stay informed on developments to protect their interests.
See More
Class Action Lawsuit Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26, 2025, and November 4, 2025, resulting in investor losses, highlighting significant transparency issues within the company.
- Allegation Details: The complaint claims that Soleno and its executives systematically minimized and failed to disclose substantial safety concerns related to the DCCR clinical trial, including excessive fluid retention among participants, which raises serious doubts about the drug's commercial viability and could undermine investor confidence.
- Investor Impact: The undisclosed safety risks associated with DCCR may lead to higher patient discontinuation rates, prescriber reluctance, and potential legal and reputational fallout, negatively affecting the company's market performance and investor sentiment.
- Action Recommendation: Affected investors are advised to apply for lead plaintiff status by May 5, 2026, to seek recovery in the lawsuit, emphasizing the legal rights and protective measures available to investors facing corporate misconduct.
See More
Class Action Lawsuit Announced Against Soleno Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Soleno Therapeutics (NASDAQ: SLNO) for common stock purchasers between March 26 and November 4, 2025, indicating potential investor losses due to undisclosed risks.
- Compensation Structure: Participants in the class action may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights in securities litigation.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety evidence related to its DCCR drug clinical trials, which could lead investors to misjudge the company's future commercial viability and associated risks.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
